National Cancer Audit Collaborating Centre

The contract will initially be delivered for NHS-funded care in England and Wales for a period of 3 years, at a maximum total budget of up to £11,145,600 GBP including VAT,
£9,288,000 GBP excluding VAT. Bids exceeding this limit will be rejected. There is potential to extend the contract for up to two additional years at a potential value of
£3,715,200 GBP per year including VAT, £3,096,000 GBP per year excluding VAT.
All pricing submissions must be in regard to this 'core' value, and not inclusive of any extension costs or aspirational intent costs, i.e. Please only submit a cost schedule up to the maximum core value of £11,145,600 GBP including VAT, £9,288,000 GBP excluding VAT.
The maximum budget ‘core’ value excludes the potential two year extension and aspirational intent as described in section 14.4 of Annex A - Service Specification.
Please note, there is no commitment by the Authority at this stage to include any aspirational intent measures. Taking the total of this aspirational intent into account, as well as the possibility that a contract extension may be offered for an additional two years, the potential ceiling value is £28,029,455 GBP including VAT, £23,357,879 GBP excluding VAT
There is also a potential that the contract price will be subject to discretionary inflationary uplifts.
Cancer is a leading cause of mortality, but it is also a leading cause of avoidable mortality in England and Wales. Cancer mortality rates in the UK are much higher than in other, comparable countries and vary greatly between different areas of the country. As part of the effort to improve treatment and outcomes and reduce variation, the National Cancer Audit Collaborating Centre (NATCAN) was established and funded by NHS England and the Welsh Government in 2022. The aim was to develop a national centre of expertise which would host the NHS national cancer audits. The audits provide regular and timely evidence to NHS services about where and how patterns of care vary...